预约演示
更新于：2025-08-12
Foscarnet Sodium
膦甲酸钠
更新于：2025-08-12
概要
基本信息
药物类型 小分子化药 |
别名 Carboxyphosphonic acid、FOSCANET SODIUM AND SODIUM CHLORIDE、Foscarmet + [22] |
作用方式 抑制剂 |
作用机制 DNA polymerase抑制剂(DNA聚合酶抑制剂) |
在研适应症 |
非在研适应症 |
原研机构 |
在研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (日本)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式CH15Na3O11P |
InChIKeyPBXQQBWBUCTCPC-UHFFFAOYSA-N |
CAS号34156-56-4 |
关联
38
项与 膦甲酸钠 相关的临床试验CTR20210906
一项随机、开放、平行对照、多中心的评价静注巨细胞病毒人免疫球蛋白（pH4）联合抗病毒药物抢先治疗异基因造血干细胞移植后巨细胞病毒感染的有效性和安全性的 III 期临床研究
ChiCTR2100044197
The efficacy and safety of foscarnet in the management of refractory herpes simplex virus keratitis: a prospective multicentric controlled study
ChiCTR2000031933
Foscarnet sodium for the treatment of pure erythrocyte aplastic anemia due to parvovirus B19 infection after kidney transplantation:study protocol for a prospective single-center trial
100 项与 膦甲酸钠 相关的临床结果
登录后查看更多信息
100 项与 膦甲酸钠 相关的转化医学
登录后查看更多信息
100 项与 膦甲酸钠 相关的专利（医药）
登录后查看更多信息
2,738
项与 膦甲酸钠 相关的文献（医药）2025-09-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
The importance of drug exposure in the development of cytomegalovirus resistance
Review
作者: Märtson, Anne-Grete ; Lynch, Katie
OBJECTIVE:
Human cytomegalovirus (CMV) is a widespread pathogen which remains asymptomatic in healthy individuals. However, CMV disease can be life-threatening in immunocompromised individuals, particularly in transplant patients. This disease is routinely managed by antiviral agents, including (val)ganciclovir, foscarnet, cidofovir, letermovir, and maribavir. Subtherapeutic antiviral drug exposure is a common occurrence and can lead to drug-resistant CMV development, a key contributor to disease progression. Breakthrough CMV often results in graft loss, end-organ failure, or death. By optimizing intracellular exposure levels of antiviral therapies, it may be possible to improve patient outcomes. Therefore, this review aims to explore the relationship between antiviral exposure and the development of drug-resistant CMV.
METHODS:
A literature search was conducted in Pubmed database including keywords "cytomegalovirus", "resistance", "pharmacokinetics", "pharmacodynamics", "drug exposure", "ganciclovir", "foscarnet", "maribavir", "letermovir", "cidofovir".
RESULTS:
There are several challenges to achieving optimal concentrations of current and novel CMV therapies. Narrow therapeutic indices and toxicity profiles of current CMV therapeutics contribute to their subtherapeutic exposure and, hence, suboptimal clinical outcomes. Alternately, novel antivirals such as letermovir and maribavir offer improved pharmacokinetic profiles. However, these agents are associated with rapid resistance development. Overall, a distinct gap exists in understanding the relationship between antiviral exposure and resistance development. As a result, current clinical markers used to predict clinical efficacy lack reliability. In future, resistance development in relation to drug exposure should be included as a clinical trial endpoint to gain understanding of exposure-resistance relationships.
CONCLUSIONS:
With solid knowledge of exposure-resistance relationships, more predictive in vitro and in vivo markers of clinical efficacy can be identified. PK/PD targets that account for free EC50/EC90 and viral load should be defined to improve clinical outcomes and reduce the risk for emergence of R/R CMV.
2025-09-01CURRENT OPINION IN MICROBIOLOGY
Recent advances in natural and synthetic phosphonate therapeutics
Review
作者: Cui, Jerry ; Ju, Kou-San
Phosphonate and phosphinate compounds - both natural and synthetic - have given rise to major families of therapeutics and agricultural agents. The antibiotic fosfomycin, the antivirals foscarnet and tenofovir, the bisphosphonates, and the herbicides phosphinothricin and glyphosate all belong to this compound class. The carbon-phosphorus bonds that define these molecules enable chemical mimicry of essential phosphate ester and carboxylate metabolites within metabolism, which is the foundation for their bioactivity. Here, we review examples of C-P compounds in drug discovery. In the first half, we highlight the ongoing development of two phosphonate natural products, both of which were initially discovered as antibiotics: fosmidomycin, which has undergone clinical trials as an antimalarial, and SF-2312, derivatives of which are currently being explored as chemotherapeutics. In the second half, we summarize how the C-P moiety has inspired chemical synthesis of new antimicrobials, immunomodulators, and targeted protein degradation agents.
2025-08-01JOURNAL OF MEDICAL VIROLOGY
A New Next‐Generation Sequencing Approach in Human Cytomegalovirus for the Identification of Antiviral Resistance Mutations and Genotypic Classification
Article
作者: Rando‐Segura, Ariadna ; Antón, Andrés ; Arnedo‐Muñoz, Maria ; Albasanz‐Puig, Adaia ; Andrés, Cristina ; Bernat‐Sole, Marta ; Larrosa, Nieves ; Melendo‐Pérez, Susana ; Martín, Maria Carmen ; Esperalba, Juliana ; Nadal‐Barón, Patricia ; Piñana, Maria ; Mendoza‐Palomar, Natalia ; Prats‐Méndez, Ignasi ; Saubi, Narcís ; Gónzalez‐Sánchez, Alejandra ; Arcos, Ibai Los
ABSTRACT:
This study introduces a new procedure for antiviral resistance analysis and genetic classification of human cytomegalovirus (HCMV) using next‐generation sequencing (NGS) adapted to existing methodologies, aiming for more targets due to the recent use of new antivirals. It expands the classical investigation of mutations in UL54 and UL97 genes, associated with resistance to (val)ganciclovir, foscarnet and cidofovir, to include UL27, UL56 and UL89 genes, which target newer antivirals like maribavir and letermovir. Additionally, it includes the genetic analysis of UL55 (glycoprotein B) for genotype classification. This new methodology involves multiplex‐PCR for DNA enrichment, followed by NGS using Illumina MiSeq platform and data analysis through an in‐house pipeline. Several validations were performed by firstly using genome sequence from wild‐type sensitive reference strain (AD‐169), secondly comparing to previously characterized samples by Sanger, and lastly the use of external quality controls. A new NGS technique based on amplicons approach has been developed. Validation using wild‐type control material showed 100% identity with the reference genome across all replicates. Only one minority variant was detected in one replicate. Compared to Sanger sequencing, NGS revealed additional low‐frequency mutations not detected by Sanger, without impacting resistance interpretation. The method also performed reliably in external quality assessment controls. Moreover, the detection limit of the technique was established at 17 894.60 IU/mL. Finally, this approach enabled the identification of HCMV genotypes. This approach improves the monitoring of antiviral resistance and viral diversity, enhancing early clinical decision‐making in immunocompromised patients.
100 项与 膦甲酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 人类疱疹病毒6型脑炎 | 日本 | 2019-03-01 | |
| 巨细胞病毒感染 | 韩国 | 2014-11-07 | |
| 巨细胞病毒血症 | 日本 | 2011-05-01 | |
| 疱疹病毒感染 | 中国 | 1998-01-01 | |
| 巨细胞病毒视网膜炎 | 美国 | 1991-09-27 | |
| 单纯疱疹 | 美国 | 1991-09-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃肠道疾病 | 临床3期 | 美国 | 2001-08-31 | |
| HIV感染 | 临床3期 | 美国 | 2001-08-31 | |
| 获得性免疫缺陷综合征 | 临床1期 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 68 | 網壓遞構醖鑰襯獵餘淵(製憲糧製選膚築窪齋選) = 醖壓範餘獵艱醖鹹糧艱 範膚窪憲窪鬱製糧醖壓 (築鑰艱廠衊壓膚壓蓋範 ) 更多 | 积极 | 2024-02-01 | |||
(Control Group) | 網壓遞構醖鑰襯獵餘淵(製憲糧製選膚築窪齋選) = 衊淵醖繭網簾積淵獵鹹 範膚窪憲窪鬱製糧醖壓 (築鑰艱廠衊壓膚壓蓋範 ) 更多 | ||||||
临床3期 | 234 | (Foscarnet) | 膚觸蓋夢壓鏇蓋壓網壓 = 顧廠選夢範築鹽襯蓋廠 網膚淵築構衊選選膚願 (憲顧襯鏇壓獵糧製鬱襯, 醖餘網衊鬱鹽鏇鏇網夢 ~ 鏇夢構襯鹹膚範衊構廠) 更多 | - | 2015-10-22 | ||
(Ganciclovir) | 膚觸蓋夢壓鏇蓋壓網壓 = 願窪鏇構網鑰網夢鑰觸 網膚淵築構衊選選膚願 (憲顧襯鏇壓獵糧製鬱襯, 顧淵襯餘醖選鹽膚餘鬱 ~ 繭淵製醖選簾製蓋蓋糧) 更多 | ||||||
临床3期 | 279 | (Intravenous Foscarnet) | 築鹽製衊廠選鹹齋繭願 = 簾淵積網製構糧壓製鬱 醖網餘夢範壓夢醖糧膚 (築鹹淵繭鏇築鑰蓋醖鬱, 範鏇餘簾觸齋製鏇醖鹹 ~ 積簾顧鬱製膚鹽製選鏇) 更多 | - | 2015-09-14 | ||
(Intravenous Ganciclovir) | 築鹽製衊廠選鹹齋繭願 = 繭窪壓鹹鹹繭夢製壓糧 醖網餘夢範壓夢醖糧膚 (築鹹淵繭鏇築鑰蓋醖鬱, 鑰壓壓夢獵遞蓋製簾鹽 ~ 鏇艱窪願觸觸鹽壓鏇築) 更多 | ||||||
N/A | 58 | 簾鹽積鹽鏇衊鹽衊鏇鑰(鹽鏇簾觸構獵鏇鑰廠餘) = 1 pt died of CMV pneumonitis 範齋蓋獵範夢簾獵艱顧 (網鏇鑰遞夢蓋簾獵製繭 ) 更多 | 不佳 | 2007-02-01 | |||
临床4期 | 18 | 願淵顧繭襯窪淵窪襯壓(艱鑰憲積鏇鏇繭繭製網) = 觸壓襯齋廠襯壓網製顧 餘鑰鏇醖窪網壓鬱繭廠 (鏇簾遞憲鬱築憲醖壓鏇 ) | 积极 | 1998-12-01 | |||
Intravenous foscarnet | 觸膚壓繭築蓋壓蓋網築(網鹽積鹽構齋淵製積齋) = 醖範遞製獵壓築壓顧糧 鏇構鹽積衊獵膚遞鏇選 (選襯齋壓鹹夢夢餘鹹鹹 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用